

This document is confidential and is proprietary to the American Chemical Society and its authors. Do not copy or disclose without written permission. If you have received this item in error, notify the sender and delete all copies.

The Integral Role of Water in the Solid-State Behaviour of the Antileishmanial Drug Miltefosine

| | |
|-------------------------------|---|
| Journal: | <i>Crystal Growth & Design</i> |
| Manuscript ID | cg-2022-00843z.R2 |
| Manuscript Type: | Article |
| Date Submitted by the Author: | 07-Sep-2022 |
| Complete List of Authors: | Hall, Amy; Durham University, Chemistry Gostick , Isobel; Durham University, Chemistry Yufit, Dmitry; Durham University, Chemistry Marchant, Gloria; Durham University, Chemistry Kirubakaran, Preyanthiny; De Montfort University, School of Pharmacy Madu, Shadrack; De Montfort University, School of Pharmacy Li , Mingzhong; De Montfort University, School of Pharmacy Steel, Patrick; Durham University, Department of Chemistry Steed, Jonathan; Durham University, Department of Chemistry |
| | |

SCHOLARONE™
Manuscripts

The Integral Role of Water in the Solid-State Behaviour of the Antileishmanial Drug Miltefosine

Amy V. Hall,^a Isobel E. F. Gostick,^a Dmitry S. Yufit,^a Gloria Y. Marchant,^a Preyanthiny Kirubakaran,^b Shadrack J. Madu,^b Mingzhong Li,^{b*} Patrick G. Steel,^a and Jonathan W. Steed.^{a*}

a) Durham University, Department of Chemistry, Lower Mountjoy, Stockton Road, Durham, DH1 3LE, UK. E-mail: jon.steed@durham.ac.uk

b) De Montfort University, School of Pharmacy, The Gateway, Leicester, LE1 9BH. E-mail: mli@dmu.ac.uk


Abstract

Miltefosine is a repurposed anticancer drug and currently the only orally administered drug approved to treat the neglected tropical disease leishmaniasis. Miltefosine is hygroscopic and must be stored at sub-zero temperatures. In this work we report the X-ray structures of miltefosine monohydrate and methanol solvate, along with 12- and 14-carbon chain analogue hydrates and a solvate. The three hydrates are all isostructural and are conformational isomorphs with $Z' = 2$. The water bridges the gap between phosphocholine head groups caused by the interdigitated bilayer structure. The two methanol solvates are also mutually isostructural with the head groups adopting a more extended conformation. Again, the solvent bridges the gap between head groups in the bilayer. No anhydrous form of miltefosine or its analogues were isolated, with dehydration resulting in significantly reduced crystallinity. This arises as a result of the integral role that hydrogen bond donors (in the form of water or solvent molecules) play in the stability of the zwitterionic structures.

Introduction

Leishmaniasis is a neglected disease that is endemic in the tropics, subtropics, and Mediterranean basin.¹ The disease is caused by protozoan parasites of the genus *Leishmania* and is transmitted to humans by infected female phlebotomine sandflies.² There are three main manifestations of leishmaniasis: visceral, cutaneous, and mucocutaneous, with visceral leishmaniasis accounting for the most fatalities if left untreated.³ There are four different medicines specified on the 22nd list of WHO Model List of Essential Medicines as treatments for leishmaniasis: amphotericin B, pentavalent antimonials, paromomycin, and miltefosine.⁴ Miltefosine is the first and only oral medication to be successfully utilized as a treatment for visceral leishmaniasis but is teratogenic and causes toxicity due to the amphiphilic and

1
2
3 zwitterionic structure of the drug (Figure 1) which irritates the gastrointestinal epithelial
4 lining.⁵⁻⁶
5
6



12 Figure 1. The zwitterionic structure of miltefosine.
13

14 Miltefosine is hygroscopic,⁷ which suggests it is most stable when surrounded by water
15 molecules. There are many studies of miltefosine at the air/water interface,⁸⁻⁹ as micelles,¹⁰⁻¹¹
16 and as liquid crystals,¹² however, the studies focussing on the solid-state structure of
17 miltefosine are limited.¹³ Hydrates or solvates can be undesirable in pharmaceutical
18 formulation. For example, hydrate forms of APIs can cause problems for the storage and shelf life of
19 the drug if dehydration takes place. Water can also cause reaction with other excipients within the
20 tablets.¹⁴⁻¹⁵ Therefore, in this work, we investigate the structure of miltefosine and structural
21 analogues (14 and 12 carbon alkyl chain analogues) with biological activity⁶ to understand the
22 role of water in the materials and determine whether it is possible to prepare an anhydrous
23 form.
24
25
26
27
28
29
30
31

32 **Results and Discussion**

33 **Solid Forms Miltefosine and its Analogues**

34 Miltefosine or *n*-hexadecylphosphocholine (PC16) is a white, hygroscopic crystalline powder
35 and is stored at -20 °C and is readily soluble in aqueous and organic solvents.⁷ Fourier-
36 transform infrared spectroscopy (FTIR) and thermogravimetric analysis (TGA)
37 characterisation of commercial samples of PC16 demonstrate that it is a monohydrate¹⁶⁻¹⁹
38 (Figure S1). No Single Crystal X-ray Diffraction (SC-XRD) structures of PC16 or closely
39 related analogues with different alkyl chain lengths are currently reported in the Cambridge
40 Structural Database (CSD),²⁰ however, a related, chiral glycerol derived phosphocholine
41 structure with an 18-carbon alkyl chain (3-octadecyl-2-methyl-D-glycero-1-phosphocholine) is
42 known and also exists as a monohydrate (refcode: DONZAH) suggesting that there may be a
43 consistent structural reason for hydrate formation in this class of compound.²¹ In DONZAH
44 the molecules pack in a bilayer with a herringbone pattern with interdigitating head groups and
45 hydrocarbon chains, alongside hydrogen bonds from the water molecule to the phosphate
46 oxygen atom at an O...P distance of 2.80 Å and a *Z'* of 1.²¹
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 To obtain the crystals of PC16, a sample was dissolved in 0.5 mL of chloroform and toluene
4 (1:1) and was sonicated at 70 °C for 1 minute and allowed to cool to room temperature which
5 yielded colourless birefringent block crystals after three weeks. The SC-XRD determination
6 revealed a centrosymmetric triclinic structure ($P\bar{1}$) with two crystallographically independent
7 molecules of miltefosine and two water molecules. The structure is thus a monohydrate with
8 $Z = 2$ (Figure 2a). The water molecule acts as a hydrogen bond bridge between the
9 phosphocholine headgroups of the two miltefosine molecules, which adopt different head
10 group conformations. The structure is thus a conformational isomorph.²²⁻²³ This observation
11 further demonstrates the conformational flexibility of this class of molecule.²⁴⁻²⁵ The aliphatic
12 chains interdigitate in the structure and the role of the water seems to be to bridge the distance
13 across the width of the interdigitated C₁₆ groups. The hydrogen bonded chain created by the
14 presence of the water molecules exhibits OH...O distances of 2.805(6) and 2.812(6) Å from
15 the hydroxy group of water to the phosphate oxygen atom of the PC16 headgroup.
16
17
18
19
20
21
22
23
24
25

26 A separate crystallisation experiment of PC16 formed colourless needle crystals from the slow
27 cooling of 2-butanol after three weeks. The SC-XRD analysis revealed a (disordered) methanol
28 solvate of PC16. The methanol appears to arise from inadvertent vapour diffusion from
29 adjacent samples. This PC16 solvate is also a $Z = 2$ conformational isomorph with a bilayer
30 structure but the head group of miltefosine adopts a more extended conformation, resulting in
31 a significantly longer c unit cell axis (27.6 vs. 24.2 Å), Figure 2b. This appears to arise from
32 the single hydrogen bond donated by methanol and the larger size of methanol compared to
33 water, preventing a hydrogen bonded chain structure. The disordered methanol molecules
34 hydrogen bond to the phosphate group of PC16 (OH...O), with hydrogen bond distances of
35 2.581(7) and 2.666(6) Å.
36
37
38
39
40
41
42
43

44 Both of these miltefosine structures imply that the presence of a solvent molecule is necessary
45 to fill gaps between the polar groups left by the bilayer structure. In order to probe the generality
46 of hydrate and solvate formation in this class of compound, we examined the structures of
47 closely related analogues of PC16. We also explored the possibility of producing an anhydrous
48 form of PC16 miltefosine itself.
49
50
51
52
53
54
55
56
57
58
59
60





Figure 2. The SC-XRD structures of the bilayer arrangement of a) PC16 monohydrate and b) PC16 (disordered) methanol solvate.

In addition to PC16, the SC-XRD structures of two shorter-chain analogues were also determined, namely, *n*-tetradecylphosphocholine (PC14) and *n*-dodecylphosphocholine (PC12). PC14 also crystallizes as both a hydrate and a methanol solvate (Figure 3a), from slow cooling crystallisations in undried acetonitrile, in the presence of methanol in the latter case. The PC14 hydrate is isostructural to the PC16 hydrate ($Z' = 2$) with a shorter *c* axis reflecting the shorter alkyl chain, and again the water plays an integral role in holding the PC14 molecules together in a hydrogen bonded chain that spans the width of the interdigitated bilayer. Hydrogen bonded OH \cdots O distances are 2.760(4) and 2.808(3) Å. The PC14 methanol solvate is also isostructural to its PC16 analogue (a conformational isomorph with $Z' = 2$) with the same more extended conformations, although in this case most of the methanol is ordered while one of the PC14 molecules in the asymmetric unit is twofold disordered. Two ordered methanol molecules are situated in discrete pockets hydrogen bonding to two of the phosphate oxygen atoms of just one of the two PC14 molecules which has a more extended conformation, with OH \cdots O distances of 2.685(4) and 2.707(4) Å. The other PC14 molecule has a more compact

1
2
3 conformation and accepts a hydrogen bond from a further disordered methanol molecule. In
4 addition, there is a small lattice void that is occupied by an additional partially occupied
5 methanol molecule.
6
7

8
9 The short chain analogue PC12 was slow cooled in acetonitrile and yielded plate crystals after
10 5 days. The SC-XRD structure reveals that this material is also isostructural to the PC16 and
11 PC14 monohydrates with the same two crystallographically independent conformations and
12 the water playing the same head group spanning role (Figure 3b), with OH \cdots O distances of
13 2.785(3) and 2.817(3) Å. In this case, however, one of the PC12 molecules is disordered across
14 two positions.
15
16
17
18
19



54 Figure 3. The SC-XRD structures of the asymmetric unit of a) PC14 solvate showing the two
55 different conformers and ordered methanol hydrogen bonding to just one of the PC14
56 molecules, and b) PC12 hydrate bilayer packing. One of the PC n molecules in the asymmetric
57
58
59
60

1
2
3 unit of both the PC14 methanol solvate and the PC12 hydrate structures are disordered over
4
5 two positions.
6
7
8
9

10 **Dehydration studies**

11 In an attempt to find an anhydrous form of PC16, a range of dehydration, recrystallisation, and
12 desolvation studies were undertaken under various conditions. The results were monitored by
13 X-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC). The DSC
14 thermogram of miltefosine monohydrate shows a dehydration endotherm with an onset
15 temperature of 97.8 °C, accompanied by a mass loss of 3.43 % by TGA at the same temperature
16 corresponding to 0.8 water molecules for formula unit. This substoichiometric value may
17 represent some empty sites in the crystals.²⁶ There are no further changes by DSC or TGA until
18 a melt-decomposition endotherm, onset 265.4 °C, in agreement with a previous report.²⁷
19 Dehydration was monitored by XRPD. A sample of miltefosine monohydrate was placed on a
20 watch glass and exposed to 120 °C in the oven for 12 to 120 hours. The XRPD pattern at each
21 interval shows a reduction in crystallinity evidenced by considerable peak broadening (Figure
22 S2). While an additional broad, low angle peak appears at 2.6 ° 2 θ from 24h drying onwards
23 which might indicate the formation of a material with a larger unit cell, samples exposed proved
24 to be sticky with a tendency to agglomerate, indicating the dried material is highly hygroscopic.
25 These dehydrated samples were analysed by DSC (Figure S3). The dehydrated samples exhibit
26 evidence for a glass transition at about 55 °C followed in some cases by a crystallization
27 exotherm. All samples showed two further broad endotherms at lower temperature than the
28 original monohydrate implying desolvation and melt-decomposition of material of lower
29 crystallinity. This study reveals that after dehydration the material becomes predominantly
30 amorphous and implies that the water molecules within PC16 hydrate are an integral structural
31 feature of the crystal packing arrangement. This is likely to arise from the lack of hydrogen
32 bond donors in PC16 itself and hence the inability of the structure to stabilise the polar
33 phosphate groups and span the breadth of the interdigitated bilayer arrangement.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 Powdered PC16 hydrate was recrystallised from both water and methanol and analysed by
52 XRPD and DSC. A comparison of the XRPD patterns of the calculated and experimental
53 powder patterns for the resulting PC16 hydrate and methanolate are shown in Figure 4. The
54 experimental patterns reproduced the calculated patterns well, although some transformation
55 of the methanolate to the hydrate by desolvation and moisture absorption appears to occur on
56
57
58
59
60

standing. The DSC thermograms of recrystallised PC16 hydrate and solvate indicate the samples are PC16 hydrate only.

The PC16 samples recrystallised from water and methanol were then desolvated by being kept in an oven for 24 hours at 60 °C. The XRPD patterns reveal no change in the case of the monohydrate and transformation of the methanolate to the monohydrate structure by adsorption of atmospheric moisture during sample handling.




Figure 4. The XRPD patterns of PC16 hydrate and PC16 solvate calculated from the SCXRD data, and the experimental patterns of PC16 hydrate and solvate recrystallised in water methanol, respectively. The recrystallised material was then desolvated.

Conclusion

The SCXRD structures of PC16 and other biologically active analogues (PC14 and PC12) demonstrate their tendency to crystallise as an isostructural series of monohydrates or methanolates. Hydrate formation is also observed in the case of the more bulky 3-octadecyl-2-methyl-D-glycero-1-phosphocholine even though the D-glycero substituent significantly alters the packing arrangement.²¹ The conformation of the head group of the PC_n molecules is dictated by the hydrogen bonding nature of the solvent and the interdigitated bilayer structure

1
2
3 is retained throughout. Each structure is a conformational isomorph with a Z' value of 2.
4 Dehydration studies of PC16 hydrate reveal that the dehydrated material is of low crystallinity
5 and is unstable and readily re-forms the hydrate. The water or methanol acts as an integral part
6 of the structure bridging the bilayer breadth and stabilising the strongly hydrogen bond acceptor
7 phosphate groups.
8
9

13 Experimental

15 General

16 All reagents and solvents were purchased from standard commercial sources and used without
17 further purification. Fourier transform infrared spectroscopy (FTIR) was carried out using a
18 Perkin Elmer Spectrum 100 spectrometer, fitted with a diamond universal Attenuated Total
19 Reflectance (uATR) accessory. Eight scans were collected for each sample at a resolution of 2
20 cm^{-1} over a wavenumber region of 4000 cm^{-1} to 500 cm^{-1} . Differential scanning calorimetric
21 studies were carried out using a NETZSCH DSC 214 Polyma (NETZSCH instrument,
22 Wolverhampton, UK) operated with nitrogen gas. Samples (approx. 4-6 mg) were weighed into an
23 aluminium pan, hermetically sealed, and the lid pierced. Samples were then heated at $20 \text{ }^\circ\text{C min}^{-1}$
24 from 20 to $300 \text{ }^\circ\text{C}$. Thermogravimetric analysis was carried out by Ruston Services using a TA
25 Instruments Q 500 TGA analyser. Between 1 and 5 mg of sample was weighed into platinum
26 pans and dry nitrogen was used as the purge gas (flow rate: 60 mL min^{-1}). X-ray powder
27 diffraction patterns were recorded on glass slides using a Bruker AXS D8 Advance
28 diffractometer with a Lynxeye Soller PSD detector or a Bruker D2 phaser diffractometer
29 equipped with a LYNXEYE XE-T detector, using $\text{Cu K}\alpha$ radiation at a wavelength of 1.5406 \AA .
30 Single crystal structures were collected at 120 K on the Bruker D8 Venture diffractometers
31 Photon III MM C14 or C7 CPAD detector, $\text{I}\mu\text{S}$ - or $\text{I}\mu\text{S}$ -III-microsource, focusing mirrors;
32 $\lambda\text{MoK}\alpha$ radiation ($\lambda = 0.71073 \text{ \AA}$) equipped with Cryostream (Oxford Cryostreams) open-flow
33 nitrogen cryostats. All structures were solved using direct methods and refined by full-matrix
34 least squares on F^2 for all data using SHELXL²⁸ and OLEX2²⁹ software. All non-disordered
35 non-hydrogen atoms were refined with anisotropic displacement parameters, disordered atoms
36 in structures PC14(solvate) and PC16(solvate) were refined with fixed equal occupancies. CH
37 hydrogen atoms were placed in calculated positions, assigned an isotropic displacement factor
38 that is a multiple of the parent carbon atom and allowed to ride. H atoms attached to oxygen
39 atoms were located on the difference map where possible or placed in calculated positions.
40 Crystallographic data for the structures have been deposited with the Cambridge
41 Crystallographic Data Centre as supplementary publication CCDC 2192420 – 2192424.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

PC16 hydrate

Miltefosine (*n*-hexadecylphosphocholine, PC16) is a white crystalline powder supplied in its hydrated form. Analysis calc. for C₂₁H₄₈NO₅P: C 59.26, H 11.37, N 3.29 %, found: C 58.98, H 11.23, N 3.32 %. Crystals of PC16 hydrate were obtained by dissolving PC16 (0.0050 g, 0.012 mmol) in chloroform/toluene (1:1, 0.5 mL), shaking the sealed vessel and sonicating at 70 °C for 1 minute and cooled to room temperature, which yielded colourless birefringent block crystals after three weeks. Crystal data: $M = 425.57 \text{ g mol}^{-1}$, triclinic, space group $P\bar{1}$ (no. 2), $a = 9.4657(7) \text{ \AA}$, $b = 10.8513(8) \text{ \AA}$, $c = 24.2121(18) \text{ \AA}$, $\alpha = 90.460(2)^\circ$, $\beta = 94.964(2)^\circ$, $\gamma = 91.296(2)^\circ$, $V = 2476.9(3) \text{ \AA}^3$, $Z = 4$, $D_c = 1.141 \text{ g/cm}^3$, $\mu = 0.139 \text{ mm}^{-1}$, $F(000) = 944.0$, 42928 reflections collected, 10780 unique ($R_{\text{int}} = 0.0692$). Final GooF = 1.051, $R_1 = 0.0626$ (7665 reflections with $I \geq 2\sigma(I)$), $wR_2 = 0.1317$ (all data), 529 parameters, 0 restraints.

PC16 solvate

Miltefosine (*n*-hexadecylphosphocholine, PC16, 0.0050 g, 0.012 mmol) was combined with 2-butanol (0.30 mL), heated to 95 °C, sealed and shaken, cooled to room temperature, and reheated to 95 °C. The resulting colourless solution was left to slow cool which yielded colourless needle crystals of a miltefosine methanol solvate after 3 weeks. The sample was inadvertently exposed to methanol in the laboratory. Solvent molecules are disordered. Crystal data: $M = 447.61 \text{ g/mol}$, triclinic, space group $P\bar{1}$ (no. 2), $a = 8.6690(9) \text{ \AA}$, $b = 10.9861(13) \text{ \AA}$, $c = 27.648(3) \text{ \AA}$, $\alpha = 95.027(5)^\circ$, $\beta = 95.074(4)^\circ$, $\gamma = 96.828(4)^\circ$, $V = 2591.4(5) \text{ \AA}^3$, $Z = 4$, $D_c = 1.147 \text{ g/cm}^3$, $\mu = 0.137 \text{ mm}^{-1}$, $F(000) = 994.0$, 24643 reflections collected, 9812 unique ($R_{\text{int}} = 0.1166$). Final GooF = 1.032, $R_1 = 0.0976$ (4625 reflections with $I \geq 2\sigma(I)$), $wR_2 = 0.2618$ (all data), 515 parameters, 0 restraints.

PC14 hydrate

n-Tetradecylphosphocholine (PC14) is a white crystalline powder and is supplied as a hydrate. Analysis calc. for C₁₉H₄₄NO₅P: C 57.40, H 11.16, N 3.52 %, found: C 57.46, H 11.03, N 3.45 %. Acetonitrile (0.80 mL) was added to *n*-tetradecylphosphocholine (0.0050 g, 0.013 mmol), heated to 80 °C, sealed and shaken, cooled to room temperature, and then heated to 80 °C. The sealed vessel was allowed to slow cool, yielding colourless birefringent plate crystals of *n*-tetradecylphosphocholine monohydrate after one week. Crystal data: $M = 397.52 \text{ g/mol}$, triclinic, space group $P\bar{1}$ (no. 2), $a = 9.4389(12) \text{ \AA}$, $b = 10.7939(13) \text{ \AA}$, $c = 22.371(3) \text{ \AA}$, $\alpha = 92.010(4)^\circ$, $\beta = 90.886(4)^\circ$, $\gamma = 91.099(4)^\circ$, $V = 2277.1(5) \text{ \AA}^3$, $Z = 4$, $D_c = 1.160 \text{ g/cm}^3$, $\mu = 0.147 \text{ mm}^{-1}$, $F(000) = 880.0$, 44906 reflections collected, 9933 unique ($R_{\text{int}} = 0.1542$). Final

GooF = 1.007, $R_1 = 0.0737$ (4573 reflections with $I \geq 2\sigma(I)$), $wR_2 = 0.1914$ (all data), 484 parameters, 0 restraints.

PC14 solvate

n-Tetradecylphosphocholine (PC14) methanol solvate was prepared as the result of a failed solution cocrystallisation of PC14 and *t*-butylhydroquinone in a 1:2 ratio, respectively. PC14 and *t*-butylhydroquinone were combined with acetonitrile (0.50 mL), heated to 80 °C, sealed, shaken and cooled to room temperature. Methanol (0.10 mL) was then added, and the mixture was heated to 60 °C before sealing, shaking, and leaving to slow cool. Colourless translucent prism shaped crystals were yielded after four weeks and was found to be a disordered methanol solvate of PC14 in a 1:2.5 ratio. Crystal data: $M = 418.55$ g/mol, space group $P\bar{1}$ (no. 2), $a = 8.6781(6)$ Å, $b = 10.9554(7)$ Å, $c = 25.0960(16)$ Å, $\alpha = 99.656(2)$ °, $\beta = 97.428(3)$ °, $\gamma = 95.037(2)$ °, $V = 2317.7(3)$ Å³, $Z = 4$, $D_c = 1.199$ g/cm³, $\mu = 0.149$ mm⁻¹, $F(000) = 926.0$, 52057 reflections collected, 12261 unique ($R_{\text{int}} = 0.0492$). Final GooF = 1.074, $R_1 = 0.1036$ (9765 reflections with $I \geq 2\sigma(I)$), $wR_2 = 0.2896$ (all data), 658 parameters, 46 restraints.

PC12 hydrate

n-Dodecylphosphocholine (PC12) is a white crystalline powder and is supplied in its hydrated form. Analysis calc. for C₁₇H₄₀NO₅P: C 55.26, H 10.91, N 3.79 %, found: C 55.68, H 10.80, N 3.67 %. Acetonitrile (0.70 mL) was added to *n*-dodecylphosphocholine (0.0050 g, 0.014 mmol), heated to 80 °C, sealed and shaken, cooled to room temperature, and then heated to 80 °C. The sealed vessel was allowed to slow cool, yielding colourless birefringent plate crystals of *n*-dodecylphosphocholine monohydrate after 5 days. Crystal data: $M = 369.47$ g/mol, , triclinic, space group $P\bar{1}$ (no. 2), $a = 9.4601(7)$ Å, $b = 10.7497(7)$ Å, $c = 20.9618(14)$ Å, $\alpha = 81.907(2)$ °, $\beta = 86.909(3)$ °, $\gamma = 89.774(2)$ °, $V = 2107.4(3)$ Å³, $Z = 4$, $D_c = 1.165$ g/cm³, $\mu = 0.154$ mm⁻¹, $F(000) = 816.0$, 40972 reflections collected, 11166 unique ($R_{\text{int}} = 0.0811$). Final GooF = 1.032, $R_1 = 0.0730$ (7489 reflections with $I \geq 2\sigma(I)$), $wR_2 = 0.2012$ (all data), 547 parameters, 0 restraints.

Acknowledgements

We thank the Engineering and Physical Sciences Research Council for funding through the GCRF scheme (EP/T020490/1).

Supplementary Information

Electronic Supplementary Information (ESI) available: IR spectra, XRPD diffractograms and DSC data. Crystal structure have been deposited with the Cambridge Structural Database CCDC 2192420 – 2192424.

References


- (1) WHO Leishmaniasis. <https://www.who.int/health-topics/leishmaniasis> (accessed 21 July 2022).
- (2) Alves, F.; Bilbe, G.; Blesson, S.; Goyal, V.; Monnerat, S.; Mowbray, C.; Ouattara, G. M.; Pecoul, B.; Rijal, S.; Rode, J.; Solomos, A.; Strub-Wourgaft, N.; Wasunna, M.; Wells, S.; Zijlstra, E. E.; Arana, B.; Alvar, J., Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives. *Clin. Microbiol. Rev.* **2018**, *31*, 30.
- (3) Burza, S.; Croft, S. L.; Boelaert, M., Leishmaniasis. *Lancet* **2018**, *392*, 951-970.
- (4) *WHO Model List Of Essential Medicines (22nd List)*. World Health Organization: 2021; Vol. 2022, p 66.
- (5) Sundar, S.; Singh, A., Chemotherapeutics of visceral leishmaniasis: present and future developments. *Parasitology* **2018**, *145*, 481-489.
- (6) Ahmed, H.; Carter, K. C.; Williams, R. A. M., Structure and Antiparasitic Activity Relationship of Alkylphosphocholine Analogues against *Leishmania donovani*. *Microorganisms* **2020**, *8*, 1117.
- (7) Dorlo, T. P. C.; Balasegaram, M.; Beijnen, J. H.; de Vries, P. J., Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. *J. Antimicrob. Chemother.* **2012**, *67*, 2576-2597.
- (8) Gomez-Serranillos, I. R.; Minones, J.; Dynarowicz-Latka, P.; Iribarnegaray, E.; Casas, M., Study of the pi-A isotherms of miltefosine monolayers spread at the air/water interface. *Phys. Chem. Chem. Phys.* **2004**, *6*, 1580-1586.
- (9) Rakotomanga, M.; Loiseau, P. M.; Saint-Pierre-Chazalet, M., Hexadecylphosphocholine interaction with lipid monolayers. *Biochim. Biophys. Acta, Biomembr.* **2004**, *1661*, 212-218.
- (10) Menez, C.; Legrand, P.; Rosilio, V.; Lesieur, S.; Barratt, G., Physicochemical characterization of molecular assemblies of miltefosine and amphotericin B. *Mol. Pharmaceutics* **2007**, *4*, 281-288.
- (11) Timko, L.; Pisarcik, M.; Mrva, M.; Garajova, M.; Juhasova, A.; Mojzic, J.; Mojzicova, G.; Bukovsky, M.; Devinsky, F.; Lukac, M., Synthesis, physicochemical properties and biological activities of novel alkylphosphocholines with foscarnet moiety. *Bioorg. Chem.* **2020**, *104*, 104224.
- (12) Malheiros, B.; de Castro, R. D.; Lotierzo, M. C.; Casadei, B. R.; Mariani, P.; Barbosa, L. R. S., Influence of hexadecylphosphocholine (Miltefosine) in phytantriol-based cubosomes: A structural investigation. *Colloids Surf., A* **2022**, *632*, 127720.
- (13) Timko, L.; Fischer-Fodor, E.; Garajova, M.; Mrva, M.; Chereches, G.; Ondriska, F.; Bukovsky, M.; Lukac, M.; Karlovska, J.; Kubincova, J.; Devinsky, F., Synthesis of structural analogues of hexadecylphosphocholine and their antineoplastic, antimicrobial and amoebicidal activity. *Eur. J. Med. Chem.* **2015**, *93*, 263-273.
- (14) Boothroyd, S.; Kerridge, A.; Broo, A.; Buttar, D.; Anwar, J., Why Do Some Molecules Form Hydrates or Solvates? *Cryst. Growth Des.* **2018**, *18*, 1903-1908.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- (15) Jurczak, E.; Mazurek, A. H.; Szeleszczuk, Ł.; Pisklak, D. M.; Zielińska-Pisklak, M., Pharmaceutical Hydrates Analysis—Overview of Methods and Recent Advances. *Pharmaceutics* **2020**, *12*, 959.
 - (16) Infantes, L.; Motherwell, S., Water clusters in organic molecular crystals. *CrystEngComm* **2002**, *4*, 454–461.
 - (17) Infantes, L.; Chisholm, J.; Motherwell, S., Extended motifs from water and chemical functional groups in organic molecular crystals. *CrystEngComm* **2003**, *5*, 480-486.
 - (18) Mascal, M.; Infantes, L.; Chisholm, J., Water Oligomers in Crystal Hydrates - What's News and What Isn't? *Angew. Chem., Int. Ed.* **2006**, *45*, 32-36.
 - (19) Infantes, L.; Fabian, L.; Motherwell, W. D. S., Organic crystal hydrates: what are the important factors for formation. *CrystEngComm* **2007**, *9*, 65-71.
 - (20) Groom, C. R.; Bruno, I. J.; Lightfoot, M. P.; Ward, S. C., The Cambridge Structural Database. *Acta Crystallogr., Sect. B: Struct. Sci., Cryst. Eng. Mater.* **2016**, *72*, 171-179.
 - (21) Pascher, I.; Sundell, S.; Eibl, H.; Harlos, K., The Single-Crystal Structure Of Octadecyl-2-Methyl-Glycerophosphocholine Monohydrate - A Multilamellar Structure With Interdigitating Head Groups And Hydrocarbon Chains. *Chem. Phys. Lipids* **1986**, *39*, 53-64.
 - (22) Bernstein, J., Conformational polymorphism. In *Organic Solid State Chemistry*, Desiraju, G. R., Ed. Elsevier: Amsterdam, 1987; pp 471-518.
 - (23) Corradini, P., X-Ray Studies of Conformation - Observation Of Different Geometries Of Same Molecule. *Chim. Ind.* **1973**, *55*, 122-129.
 - (24) Yaseen, M.; Lu, J. R.; Webster, J. R. P.; Penfold, J., The structure of zwitterionic phosphocholine surfactant monolayers. *Langmuir* **2006**, *22*, 5825-5832.
 - (25) Zarbakhsh, A.; Querol, A.; Bowers, J.; Yaseen, M.; Lu, J. R.; Webster, J. R. P., Neutron reflection from the liquid-liquid interface: Adsorption of hexadecylphosphorylcholine to the hexadecane-aqueous solution interface. *Langmuir* **2005**, *21*, 11704-11709.
 - (26) Braun, D. E.; Koztecki, L. H.; McMahon, J. A.; Price, S. L.; Reutzel-Edens, S. M., Navigating the Waters of Unconventional Crystalline Hydrates. *Mol. Pharm.* **2015**, *12*, 3069-3088.
 - (27) Das, S.; Khan, W.; Mohsin, S.; Kumar, N., Miltefosine loaded albumin microparticles for treatment of visceral leishmaniasis: formulation development and in vitro evaluation. *Polymers for Advanced Technologies* **2011**, *22*, 172-179.
 - (28) Sheldrick, G. M., Crystal structure refinement with SHELXL. *Acta Crystallogr., Sect. C: Struct. Chem.* **2015**, *71*, 3-8.
 - (29) Dolomanov, O. V.; Bourhis, L. J.; Gildea, R. J.; Howard, J. A. K.; Puschmann, H., OLEX2: a complete structure solution, refinement and analysis program. *J. Appl. Crystallogr.* **2009**, *42*, 339-341.

1
2
3 **For Table of Contents Only**

4
5 **The Integral Role of Water in the Solid-State Behaviour of the Antileishmanial**
6
7 **Drug Miltefosine**

8
9 Amy V. Hall, Isobel E. F. Gostick, Dmitry S. Yufit, Gloria Y. Marchant, Preyanthiny
10 Kirubakaran, Shadrack J. Madu, Mingzhong Li,* Patrick G. Steel, and Jonathan W. Steed.*



22
23 Hydrogen bond donors in the form of water or solvent molecules play a key role in the stability
24 of the anti-leishmaniasis drug miltefosine